Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients
L Lunardon, KJ Tsai, KJ Propert, N Fett… - Archives of …, 2012 - jamanetwork.com
Background We conducted a retrospective study of patients with pemphigus vulgaris (n= 24)
and foliaceus (n= 7) treated with adjuvant rituximab to determine efficacy and adverse
events. The end point for efficacy was complete remission of disease taking no or minimal
therapy. Observations Eighteen patients (58%) achieved the study end point. Of these, 13
patients achieved complete remission off systemic therapy. Patients achieving the study end
point had a median disease duration before rituximab therapy of 19 months vs 86 months in …
and foliaceus (n= 7) treated with adjuvant rituximab to determine efficacy and adverse
events. The end point for efficacy was complete remission of disease taking no or minimal
therapy. Observations Eighteen patients (58%) achieved the study end point. Of these, 13
patients achieved complete remission off systemic therapy. Patients achieving the study end
point had a median disease duration before rituximab therapy of 19 months vs 86 months in …
